摘要
本试验旨在评价舒普深治疗下呼吸道感染的临床有效性及安全性，选用泰能作对照。共入选病例７３例，可评价疗效者６１例，其中试验组（舒普深）与对照组（泰能）分别为３１例与３０例。安全性评价入选病例６３例，两组分别为３１与３２例。给药方法两药均为每次１．０～２．０ｇ，每日２次，疗程７～１４天。结果试验组与对照组的临床有效率分别为９３．５％和９３．３％。６１例患者中共分离出致病菌４９株，其中产酶菌占２／３以上。治疗结束后两组细菌清除率分别为９２．０％与９１．７％，不良反应发生率分别为３．２％和１０．０％，纸片药敏试验敏感菌百分率分别为９５．９％和９３．９％。以上结果经统计学处理两组差异无显著性。提示两药均有很强的抗细菌感染作用，但舒普深的耐受性更好。
ThepurposeoftheclinicalstudyistoevaluatetheefficacyandsaftyofSulperazone(SPZ)(sulbactam/cefoperazone)comparitedwithtienaminthetreatmentoflowerrespariatorytractin-fections.Atotalof73patientsenroledinthestudy.61patientswereevaluatedforefficacy(SPZ31,TIM30)and63patientswereevaluatedforsafty(SPZ31,TIM32).Drugswereadministeredtwiceadayfor7～14days,atadailydoseofeither2.0～4.0gofsulperazoneor2.0～4.0gtienam.Theoveralclinicaleficacyratesofsulperazoneandtienamwere93.5%and93.3%,respectively.Totalpathogenswereisolatedfrom49of61patientspriortotreatment.Overtwo～thirdsoftheisolates(37/48,77.1%)wereβ-lactammaseproducingstrains.Thebacterialogicalclearnceratewas92.0%and91.7%forbothgroups.TheincidenceofadversedrugreactionsforSPZandTIMwere3.2%and10.0%,respec-tively.Thesusceptibilityratesofthebacteriaisolatedtofivedrugs:sulperazone,tienam,ceftazidime,ceftriaxoneandcefotaximewere95.9%,93.9%,96.0%,70.0%,and80.0%respecttively.Thesus-ceptibilityrateofsulperazoenewassignificant.
出处
《中华内科杂志》
CAS
CSCD
北大核心
1996年第12期819-823,共5页
Chinese Journal of Internal Medicine
关键词
舒普深
泰能
呼吸道感染
药物疗法
RandomizedcontroledtrialsTreatmentoutcomeSulperazoneTienam
